Chemical compound and its use

Abstract

The present application relates to a novel tetrahydroquinoline derivative, to a process for its preparation, to its use on its own or in combination for treating and/or preventing diseases and to its use for preparing medicaments, in particular as an inhibitor of the cholesterol ester transfer protein (CETP) for the treatment and/or prevention of cardiovascular disorders, in particular hypolipoproteinaemias, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, hypercholesterolaemias and arteriosclerosis.

1 - 10 . (canceled) 
     
     
         11 . A method for the primary and/or secondary prevention of coronary heart disease in a humans or animal comprising administering an effective amount of a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       in which R represents cyclopentyl or isopropyl, and salts thereof. 
     
     
         12 . A method for the treatment and/or prevention of hypolipoproteinaemias, dyslipidaemias, hypetriglyceridaemias, hyperlipidaemias, hypercholesterolaemias, arteriosclerosis, restenosis, adiposity, obesity, diabetes, stroke and Alzheimer's disease in a humans or animal by administering an effective amount of a compound of formula (I). 
       
         
           
           
               
               
           
         
       
       in which R represents cyclopentyl or isopropyl, and salts thereof. 
     
     
         13 - 14 . (canceled) 
     
     
         15 . The method of  claim 11 , wherein the compound of formula (I) is administered as a pharmaceutical composition comprising the compound in combination with an inert nontoxic pharmaceutically suitable auxiliary. 
     
     
         16 . The method of  claim 11 , wherein the compound of formula (I) is administered as a pharmaceutical composition comprising the compound and at least one active compound selected from the group consisting of an antidiabetic, a platelet aggregation inhibitor, an anticoagulant, a calcium antagonist, an angiotensin AII antagonist, an ACE inhibitor, a beta blocker, a phosphodiesterase inhibitor, a stimulator of soluble guanylate cyclase, a cGMP enhancer, a diuretic, a thyroid receptor agonist, an HMG-CoA reductase inhibitor, a squalene synthase inhibitor, a squalene epoxidase inhibitor, a, oxidosqualene cyclase inhibitor, an ACAT inhibitor, a MTP inhibitor, a PPAR agonist, a fibrate, a lipase inhibitor, a cholesterol absorption inhibitor, a bile acid reabsorption inhibitor, a polymeric bile acid adsorber and a lipoprotein(a) antagonist. 
     
     
         17 . The method of  claim 12 , wherein the compound of formula (I) is administered as a pharmaceutical composition comprising the compound in combination with an inert nontoxic pharmaceutically suitable auxiliary. 
     
     
         18 . The method of  claim 12 , wherein the compound of formula (I) is administered as a pharmaceutical composition comprising the compound and at least one active compound selected from the group consisting of an antidiabetic, a platelet aggregation inhibitor, an anticoagulant, a calcium antagonist, an angiotensin AII antagonist, an ACE inhibitor, a beta blocker, a phosphodiesterase inhibitor, a stimulator of soluble guanylate cyclase, a cGMP enhancer, a diuretic, a thyroid receptor agonist, an HMG-CoA reductase inhibitor, a squalene synthase inhibitor, a squalene epoxidase inhibitor, a, oxidosqualene cyclase inhibitor, an ACAT inhibitor, a MTP inhibitor, a PPAR agonist, a fibrate, a lipase inhibitor, a cholesterol absorption inhibitor, a bile acid reabsorption inhibitor, a polymeric bile acid adsorber and a lipoprotein(a) antagonist.